Skip to Content

Edarbi Side Effects

Generic Name: azilsartan medoxomil

Note: This page contains information about the side effects of azilsartan medoxomil. Some of the dosage forms included on this document may not apply to the brand name Edarbi.

Not all side effects for Edarbi may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to azilsartan medoxomil: oral tablet

In addition to its needed effects, some unwanted effects may be caused by azilsartan medoxomil (the active ingredient contained in Edarbi). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking azilsartan medoxomil:

Rare
  • Blurred vision
  • confusion
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • sweating
  • unusual tiredness or weakness

Some of the side effects that can occur with azilsartan medoxomil may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Less common
  • Diarrhea
Rare
  • Cough
  • dizziness
  • lack or loss of strength
  • muscle spasm
  • nausea

For Healthcare Professionals

Applies to azilsartan medoxomil: oral tablet

General

The most common side effects were diarrhea, dizziness, headache, dyslipidemia, cough, and increased blood creatine phosphokinase.[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea
Uncommon (0.1% to 1%): Nausea[Ref]

Nervous system

Common (1% to 10%): Dizziness, headache
Frequency not reported: Dizziness postural[Ref]

Metabolic

Common (1% to 10%): Dyslipidemia
Uncommon (0.1% to 1%): Blood uric acid increased, hyperuricemia[Ref]

Respiratory

Common (1% to 10%): Cough[Ref]

Musculoskeletal

Common (1% to 10%): Blood creatine phosphokinase increased
Uncommon (0.1% to 1%): Muscle spasm[Ref]

Dermatologic

Uncommon (0.1% to 1%): Rash, pruritus
Rare (less than 0.1%): Angioedema[Ref]

Other

Uncommon (0.1% to 1%): Fatigue, peripheral edema
Frequency not reported: Asthenia[Ref]

Hematologic

Uncommon (0.1% to 1%): Low hemoglobin, low hematocrit, low RBC counts[Ref]

Renal

Uncommon (0.1% to 1%): Blood creatinine increased[Ref]

Cardiovascular

Uncommon (0.1% to 1%): Hypotension[Ref]

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. "Product Information. Edarbi (azilsartan)." Takeda Pharmaceuticals America, Lincolnshire, IL.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web1)